Riskpilot← Back to searchSign inGet full accessAPIM THERAPEUTICS AS
ASActiveOrg 894298952Yrjars Gate 29, 7130 BrekstadWholesale of pharmaceutical and medical goods · NACE 4646Est. 20092 employees
Revenue 2024
NOK 65K
EBITDA margin
-20331.6%
+30% vs 2023
Equity ratio
97.7%
Financial strength
Net profit 2024
NOK -45,9M
-148% vs 2023
| Revenue | NOK 65K | — |
| EBITDA | NOK -13,2M | +30% |
| Net profit | NOK -45,9M | -148% |
| Total assets | NOK 20,7M | -66% |
| Equity | NOK 20,2M | -67% |
| Employees | 2 | — |
Legal name
APIM THERAPEUTICS AS
Org number
894298952
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
29. august 2009
Share capital
NOK 2 265 695
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Utvikling, produksjon og markedsføring/salg av produkter/tjenester innen legemidler, samt annen virksomhet som naturlig står i tilknytning til dette.
Address
Yrjars Gate 29, 7130 Brekstad
Phone
+4773204540
Email
contact@apimtherapeutics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 500 | 0 | 60 | 1 553 | 4 215 | 5 907 | 611 | 15 | 0 | 0 | 0 | 0 | 104 | 0 | 65 |
| Staff expenses | −0 | −157 | −239 | −492 | −774 | −723 | −723 | −723 | −906 | −814 | −1 043 | −1 903 | −1 843 | −1 880 | −1 848 | −1 410 |
| EBITDA | −664 | −3 085 | −1 480 | −3 091 | −4 926 | −5 564 | −5 928 | −5 930 | −3 403 | −5 570 | −6 519 | −12 264 | −14 767 | −26 827 | −18 963 | −13 207 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −664 | −3 085 | −1 480 | −3 091 | −4 926 | −5 564 | −5 928 | −5 930 | −3 403 | −5 570 | −6 519 | −12 264 | −14 767 | −26 827 | −18 963 | −13 207 |
| Net financials | 0 | −3 | 8 | 32 | −79 | −365 | 129 | 28 | 9 | 71 | 215 | 495 | −70 | 471 | 475 | −32 708 |
| Profit before tax | −664 | −3 088 | −1 472 | −3 059 | −5 005 | −5 928 | −5 799 | −5 902 | −3 393 | −5 499 | −6 303 | −11 769 | −14 836 | −26 357 | −18 488 | −45 915 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −664 | −3 088 | −1 472 | −3 059 | −5 005 | −5 928 | −5 799 | −5 902 | −3 393 | −5 499 | −6 303 | −11 769 | −14 836 | −26 357 | −18 488 | −45 915 |
| Item | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 881 | 1 906 | 6 047 | 9 726 | 11 776 | 5 944 | 13 391 | 11 559 | 33 057 | 33 352 | 37 152 | 35 388 | 79 305 | 72 821 | 61 690 | 20 676 |
| Equity | −560 | 1 352 | 5 381 | 8 321 | 3 316 | 3 928 | 10 451 | 9 555 | 31 249 | 25 750 | 34 927 | 23 157 | 76 703 | 63 869 | 60 431 | 20 195 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 000 | 0 | 0 | 0 | 0 |
| Short-term debt | 1 440 | 554 | 667 | 1 404 | 8 459 | 2 017 | 1 851 | 915 | 1 808 | 7 602 | 2 226 | 2 231 | 2 602 | 8 952 | 1 260 | 414 |
| Total debt | 1 440 | 554 | 667 | 1 404 | 8 459 | 2 017 | 1 851 | 915 | 1 808 | 7 602 | 2 226 | 12 231 | 2 602 | 8 952 | 1 260 | 414 |
EBITDA margin
-20331.6%
This company
15.8%
Market median
-128781% vs market
20092024
Equity ratio
97.7%
This company
38.2%
Market median
+156% vs market
20092024
Return on equity
-227.4%
This company
18.4%
Market median
-1336% vs market
20092024
Net profit margin
-70682.7%
This company
8.1%
Market median
-872726% vs market
20092024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20092024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20092024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-06-18 – 2009-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EW Observer | Observer | 2023 | — | — |
KA Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Chairman | 2023 | — | — | |
| Board of Directors | 2023 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Sarsia Seed As | Company | 28.2% | 28.2% | 2024 |
Trond Mohn Forskningsstiftelse | Company | 17.4% | 17.4% | 2024 |
Investinor Direkte As | Company | 15.9% | 15.9% | 2024 |
Norsk Innovasjonskapital Iii As | Company | 15.5% | 15.5% | 2022 |
| Individual | 2.9% | 2.9% | 2022 | |
Birk Venture As | Company | 2.8% | 2.8% | 2024 |
Altitude Explorer As | Company | 2.7% | 2.7% | 2024 |
Skips As Tudor | Company | 2.4% | 2.4% | 2024 |
Krakr As | Company | 2.1% | 2.1% | 2024 |
| Individual | 2.0% | 2.0% | 2024 | |
Ro Invest As | Company | 1.6% | 1.6% | 2024 |
Norda Asa | Company | 1.5% | 1.5% | 2024 |
| Individual | 1.4% | 1.4% | 2024 | |
Hmh Invest As | Company | 1.2% | 1.2% | 2024 |
Helift As | Company | 1.2% | 1.2% | 2024 |
H5 Vekst As | Company | 1.1% | 1.1% | 2024 |
Chamar As | Company | 1.1% | 1.1% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NÆRINGS- OG FISKERIDEPARTEMENTETInvestinor AsInvestinor Direkte As
APIM THERAPEUTICS AS (this company)Board members of APIM THERAPEUTICS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Wold | Observer | 0 companies |
| Konstantinos Alevizopoulos | Chief Executive Officer | 0 companies |
| Birgitte Gangmark Villmo | Board of Directors | 0 companies |
| Martin Welschof | Board of Directors | 0 companies |
| Farzad Abdi-Dezfuli | Board of Directors | 0 companies |
| Jørgen Andre Nilsen | Board of Directors | 0 companies |
| Gökhan Batur | Board of Directors | 0 companies |
| Erlend Petter Skagseth | Chairman | 0 companies |
| Stener Kvinnsland | Board of Directors | 0 companies |